Log in

NASDAQ:AXGTAxovant Gene Therapies Stock Price, Forecast & News

$2.88
+0.03 (+1.05 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.82
Now: $2.88
$2.92
50-Day Range
$2.74
MA: $3.14
$3.48
52-Week Range
$1.41
Now: $2.88
$8.08
Volume69,400 shs
Average Volume167,453 shs
Market Capitalization$116.18 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in New York, New York. Axovant Gene Therapies Ltd. operates as a subsidiary of Roivant Sciences Ltd.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXGT
CUSIPN/A
CIKN/A
Phone833-296-8268

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.67 per share

Profitability

Net Income$-72,630,000.00

Miscellaneous

Employees45
Market Cap$116.18 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive AXGT News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGT and its competitors with MarketBeat's FREE daily newsletter.

Axovant Gene Therapies (NASDAQ:AXGT) Frequently Asked Questions

How has Axovant Gene Therapies' stock been impacted by COVID-19 (Coronavirus)?

Axovant Gene Therapies' stock was trading at $2.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXGT shares have increased by 34.0% and is now trading at $2.88. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Axovant Gene Therapies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Gene Therapies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Axovant Gene Therapies.

When is Axovant Gene Therapies' next earnings date?

Axovant Gene Therapies is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Axovant Gene Therapies.

How were Axovant Gene Therapies' earnings last quarter?

Axovant Gene Therapies Ltd (NASDAQ:AXGT) issued its quarterly earnings data on Wednesday, June, 10th. The company reported ($0.54) EPS for the quarter, topping the Zacks' consensus estimate of ($0.56) by $0.02. View Axovant Gene Therapies' earnings history.

When did Axovant Gene Therapies' stock split? How did Axovant Gene Therapies' stock split work?

Axovant Gene Therapies shares reverse split before market open on Wednesday, May 8th 2019. The 1-8 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 7th 2019. An investor that had 100 shares of Axovant Gene Therapies stock prior to the reverse split would have 13 shares after the split.

What price target have analysts set for AXGT?

4 brokers have issued 12-month price targets for Axovant Gene Therapies' stock. Their forecasts range from $11.00 to $15.00. On average, they anticipate Axovant Gene Therapies' share price to reach $13.00 in the next twelve months. This suggests a possible upside of 351.4% from the stock's current price. View analysts' price targets for Axovant Gene Therapies.

Has Axovant Gene Therapies been receiving favorable news coverage?

Media coverage about AXGT stock has been trending somewhat negative on Saturday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Axovant Gene Therapies earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Axovant Gene Therapies.

Are investors shorting Axovant Gene Therapies?

Axovant Gene Therapies saw a drop in short interest in June. As of June 30th, there was short interest totaling 263,700 shares, a drop of 10.2% from the June 15th total of 293,600 shares. Based on an average trading volume of 160,900 shares, the short-interest ratio is presently 1.6 days. Currently, 1.2% of the company's stock are short sold. View Axovant Gene Therapies' Current Options Chain.

Who are some of Axovant Gene Therapies' key competitors?

What other stocks do shareholders of Axovant Gene Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axovant Gene Therapies investors own include Amarin (AMRN), Agile Therapeutics (AGRX), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), Opko Health (OPK), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Aileron Therapeutics (ALRN), Genocea Biosciences (GNCA) and Aduro BioTech (ADRO).

Who are Axovant Gene Therapies' key executives?

Axovant Gene Therapies' management team includes the following people:
  • Dr. Pavan Cheruvu M.D., CEO & Director (Age 37)
  • Dr. Gregory M. Weinhoff, Principal Financial & Accounting Officer (Age 48)
  • Dr. David T. Hung M.D., Scientific Advisor of Group (Age 61)
  • Dr. Fraser Wright, Chief Technology Officer
  • Ms. Tricia Truehart, Head of Investor Relations

What is Axovant Gene Therapies' stock symbol?

Axovant Gene Therapies trades on the NASDAQ under the ticker symbol "AXGT."

How do I buy shares of Axovant Gene Therapies?

Shares of AXGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Axovant Gene Therapies' stock price today?

One share of AXGT stock can currently be purchased for approximately $2.88.

How big of a company is Axovant Gene Therapies?

Axovant Gene Therapies has a market capitalization of $116.18 million. The company earns $-72,630,000.00 in net income (profit) each year or ($2.93) on an earnings per share basis. Axovant Gene Therapies employs 45 workers across the globe.

What is Axovant Gene Therapies' official website?

The official website for Axovant Gene Therapies is www.axovant.com.

How can I contact Axovant Gene Therapies?

Axovant Gene Therapies' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, 10036. The company can be reached via phone at 833-296-8268 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.